About
Cell Penetrating Peptides
Areas of Focus
Categories
Gene Therapy, RNA & Peptide Therapy
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
62
By Phase
PHASE2: 1PHASE1: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06650514Collaborator
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma
PHASE2Recruiting
10 participants
Started: Dec 27, 2024 · Completed: Dec 31, 2026
NCT06059001Lead Sponsor
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered Iv in Patients with PDAC
PHASE1Recruiting
30 participants
Started: Aug 31, 2023 · Completed: Mar 31, 2026
NCT04808362Lead Sponsor
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
PHASE1/PHASE2Terminated
22 participants
Started: Apr 28, 2021 · Completed: Jan 11, 2023
Locations (1)
Headquarters
Barcelona, Spain
Map
Loading map...